TRYNGOLZA (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRYNGOLZA (AUTOINJECTOR) (TRYNGOLZA (AUTOINJECTOR)).
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
| Metabolism | Metabolized primarily by CYP3A4 and CYP2C8. |
| Excretion | Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition. |
| Protein binding | Approximately 99% bound; primarily to albumin and other plasma proteins. |
| Volume of Distribution | Vd is approximately 0.08 L/kg, indicating distribution primarily within the vascular space. |
| Bioavailability | Subcutaneous: Approximately 40–60% after autoinjector administration. |
| Onset of Action | Subcutaneous: Clinical effect (reduction in LDL-C) observed within 2–4 weeks after first dose. |
| Duration of Action | Duration of effect is approximately 2–4 weeks post-dose; repeat dosing every 2–4 weeks is required to maintain LDL-C reduction. |
| Molecular Weight | 146000 |
0.5 mg subcutaneously once daily.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential comorbidities. |
| 1st trimester | No adequate human data; animal studies show risk. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | Limited human data; potential fetal harm based on mechanism. Use only if clearly needed. |
| 3rd trimester | May cause fetal harm based on mechanism; avoid use in third trimester unless essential. |
Clinical note
Comprehensive clinical and safety monograph for TRYNGOLZA (AUTOINJECTOR) (TRYNGOLZA (AUTOINJECTOR)).
| Placental transfer | Expected to cross placenta; molecular weight suggests transfer. No human data available. |
| Breastfeeding | No data on presence in human milk; potential for serious adverse reactions in nursing infants. Consider discontinuing breastfeeding or drug. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to drug or any ingredient
| Precautions | Increased risk of serious infections, Malignancies including lymphoma, Hepatotoxicity, Lipid abnormalities, Hypersensitivity reactions |
| Food/Dietary | Avoid taking with meals; administer at least 1 hour before or 2 hours after eating to prevent nausea and vomiting. No specific foods are contraindicated, but high-fat meals may delay absorption. |
| Clinical Pearls | Bethanechol is a parasympathomimetic agent used primarily for nonobstructive urinary retention. Administer 1 hour before or 2 hours after meals to reduce nausea and vomiting. Monitor for bradycardia, hypotension, and bronchospasm, especially in patients with asthma or cardiac disease. Subcutaneous administration is preferred for acute treatment; oral route has erratic absorption. Have atropine available as antidote. Avoid use in patients with mechanical obstruction, hyperthyroidism, or peptic ulcer disease. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, craniofacial anomalies, and cardiovascular defects. Second and third trimesters: risk of oligohydramnios, fetal renal impairment, and skeletal abnormalities. Contraindicated in pregnancy. |
| Fetal Monitoring | If inadvertent exposure occurs, monitor for oligohydramnios via ultrasound, fetal growth restriction, and fetal renal function. Perform pregnancy test before initiation and monthly during treatment. |
| Fertility Effects | May impair fertility in females based on animal studies showing ovarian and uterine effects. Reversible upon discontinuation. No human data available. |
| Patient Advice | Take this medication on an empty stomach to minimize side effects. · Do not take with food or within 1 hour after eating. · Avoid driving or operating machinery until you know how this medication affects you. · Report signs of overdose: excessive sweating, salivation, tearing, or muscle weakness. · Do not stop taking abruptly without consulting your healthcare provider. · Store at room temperature away from moisture and heat. |